Physician
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $176.33M by Medicaid between Jan 2018 and Dec 2024, across 713 billing codes. Its largest line is 90791, psychiatric diagnostic evaluation — 9.0% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
NEW YORK, NY 10016
NEW YORK, NY 10016
33aNPI1073535027assigned 07/25/2006
33bProvider typeInternal Medicine Physician
28Total paid$176.33M
24GClaims3,438,615
24DCodes billed713
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#3 of 6,049
Median peer was paid$11K
This provider vs. median15,587×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 62,526 | $306K | |
| 2019 | 205,514 | $8.78M | |
| 2020 | 504,609 | $26.06M | |
| 2021 | 810,623 | $38.25M | |
| 2022 | 771,825 | $41.81M | |
| 2023 | 573,143 | $32.74M | |
| 2024incomplete | 510,375 | $28.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 9.0% | 15,531 | 13,883 | $15.81M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.0% | 174,819 | 154,116 | $15.81M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.3% | 77,834 | 67,355 | $12.96M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.5% | 62,824 | 55,552 | $11.43M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.4% | 90,473 | 82,123 | $9.60M |
| J9271 | Injection, pembrolizumab, 1 mg | 4.0% | 737 | 589 | $7.12M |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 2.0% | 91,030 | 11,739 | $3.59M |
| 36415 | Collection of venous blood by venipuncture | 2.0% | 246,272 | 139,049 | $3.59M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.0% | 57,708 | 50,666 | $3.58M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 1.9% | 26,403 | 15,587 | $3.42M |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 1.9% | 19,371 | 9,278 | $3.35M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 16,234 | 14,610 | $3.17M |
701 more codes
| 99204 | Doctor's office visit, new patient (more involved) | 1.6% | 17,927 | $2.77M |
| 99203 | Doctor's office visit, new patient (routine) | 1.5% | 22,269 | $2.69M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.3% | 36,311 | $2.30M |
| 99215 | Doctor's office visit, returning patient (complex) | 1.3% | 15,675 | $2.26M |
| 99442 | 1.2% | 35,734 | $2.17M | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.1% | 27,891 | $1.92M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 38,214 | $1.87M |
| 99443 | 1.0% | 22,121 | $1.80M | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.0% | 13,551 | $1.78M |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 8,975 | $1.69M |
| D0999 | Unspecified diagnostic procedure, by report | <1% | 9,960 | $1.59M |
| 99285 | Emergency room visit (most serious) | <1% | 8,543 | $1.58M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 70,971 | $1.49M |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 8,444 | $1.20M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,525 | $1.05M |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 844 | $980K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 9,607 | $969K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,927 | $963K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 8,850 | $937K |
| 81408 | <1% | 667 | $932K | |
| 99205 | Prolong outpt/office vis | <1% | 4,654 | $879K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 37,231 | $811K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 17,502 | $777K |
| 97802 | <1% | 9,466 | $772K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 9,530 | $759K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 728 | $756K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 4,259 | $724K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 20,246 | $705K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 7,506 | $690K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,537 | $637K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,884 | $615K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 19,116 | $606K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,251 | $581K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 61,407 | $568K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,644 | $565K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 3,801 | $564K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 7,565 | $552K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 25,560 | $521K |
| 90836 | <1% | 4,734 | $504K | |
| 99441 | <1% | 12,152 | $500K | |
| 80053 | Comprehensive metabolic panel | <1% | 38,377 | $495K |
| H0037 | Community psychiatric supportive treatment program, per diem | <1% | 397 | $487K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 17,839 | $485K |
| GZ3ZZZZ | <1% | 222 | $476K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 2,591 | $465K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 830 | $458K |
| 90378 | <1% | 226 | $455K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 16,370 | $455K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 637 | $453K |
| 80061 | Lipid panel | <1% | 41,303 | $441K |
| 74220 | <1% | 6,544 | $434K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 27,574 | $434K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 994 | $426K |
| 85027 | <1% | 102,525 | $420K | |
| 90461 | <1% | 17,485 | $412K | |
| 59025 | Fetal non-stress test | <1% | 3,067 | $411K |
| 86480 | <1% | 7,413 | $408K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,461 | $390K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 5,561 | $388K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,172 | $376K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,753 | $367K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 5,817 | $364K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,398 | $357K |
| 87536 | <1% | 3,800 | $357K | |
| D0210 | Intraoral - complete series of radiographic images | <1% | 484 | $348K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 22,684 | $347K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,802 | $333K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 30,631 | $332K |
| 86850 | <1% | 17,637 | $320K | |
| 97803 | <1% | 6,673 | $315K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 34,056 | $312K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 48,446 | $312K |
| 70486 | <1% | 2,502 | $307K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 4,397 | $297K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25,343 | $286K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 12,267 | $284K |
| 80076 | <1% | 41,872 | $281K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 984 | $279K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 8,297 | $271K |
| 96415 | <1% | 1,214 | $269K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 397 | $266K |
| 90750 | <1% | 2,868 | $264K | |
| 84207 | <1% | 10,074 | $261K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 413 | $261K |
| 71250 | <1% | 1,189 | $252K | |
| 90651 | <1% | 1,946 | $248K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 620 | $241K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,397 | $240K |
| 86901 | <1% | 18,130 | $236K | |
| 90677 | <1% | 1,951 | $231K | |
| 86703 | <1% | 16,391 | $224K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 3,839 | $222K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,654 | $220K |
| 76770 | <1% | 1,388 | $218K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 1,990 | $216K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,163 | $213K |
| 97804 | <1% | 7,596 | $209K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 115 | $208K |
| 86360 | <1% | 4,422 | $206K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 13,599 | $202K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,720 | $200K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,564 | $192K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 8,049 | $186K |
| 82607 | <1% | 15,347 | $183K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,618 | $168K |
| 86359 | <1% | 4,412 | $167K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,245 | $166K |
| 90715 | <1% | 6,772 | $163K | |
| 76642 | <1% | 1,756 | $160K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 640 | $160K |
| 0002A | <1% | 5,607 | $159K | |
| 82728 | <1% | 16,703 | $159K | |
| H0001 | Alcohol and/or drug assessment | <1% | 879 | $154K |
| 84425 | <1% | 9,725 | $153K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,580 | $153K |
| 86769 | <1% | 5,352 | $152K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,838 | $151K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,089 | $150K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,223 | $149K |
| 93970 | <1% | 1,144 | $149K | |
| 0001A | <1% | 5,835 | $148K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,231 | $146K |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 857 | $144K |
| 86900 | <1% | 17,662 | $144K | |
| D1120 | Dental cleaning, child | <1% | 10,872 | $143K |
| 86780 | <1% | 13,736 | $142K | |
| 83655 | <1% | 13,074 | $141K | |
| D1351 | Sealant - per tooth | <1% | 2,612 | $140K |
| 81161 | <1% | 650 | $139K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,975 | $138K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 22,218 | $137K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 2,793 | $132K |
| 0004A | <1% | 3,456 | $131K | |
| 90746 | <1% | 2,255 | $128K | |
| 77066 | Tomosynthesis, mammo | <1% | 863 | $128K |
| 88307 | <1% | 1,517 | $126K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,502 | $125K |
| J2794 | Injection, risperidone (risperdal consta), 0.5 mg | <1% | 205 | $124K |
| 76818 | <1% | 1,077 | $121K | |
| 86803 | <1% | 10,867 | $120K | |
| 12011 | <1% | 430 | $119K | |
| 81329 | <1% | 943 | $117K | |
| 12001 | <1% | 429 | $117K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,454 | $116K |
| 84439 | <1% | 16,555 | $113K | |
| 77062 | <1% | 699 | $113K | |
| D0120 | Dental checkup, returning patient | <1% | 12,762 | $111K |
| 81405 | <1% | 526 | $111K | |
| 92134 | <1% | 2,493 | $111K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 486 | $106K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 1,076 | $106K |
| 84134 | <1% | 11,067 | $104K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 106 | $104K |
| 96417 | <1% | 1,362 | $102K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,396 | $99K |
| 84590 | <1% | 9,337 | $96K | |
| 94060 | <1% | 1,834 | $94K | |
| 92083 | <1% | 1,543 | $92K | |
| 96156 | <1% | 1,126 | $92K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 574 | $92K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,996 | $92K |
| 76536 | <1% | 840 | $91K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,038 | $89K |
| 83550 | <1% | 15,834 | $87K | |
| 96367 | <1% | 1,851 | $86K | |
| 77065 | Tomosynthesis, mammo | <1% | 749 | $86K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,938 | $85K |
| 73130 | <1% | 3,853 | $85K | |
| 99381 | <1% | 988 | $83K | |
| 73564 | <1% | 2,746 | $83K | |
| 0124A | <1% | 1,862 | $82K | |
| 90674 | <1% | 3,904 | $82K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,725 | $81K |
| 90686 | <1% | 9,037 | $80K | |
| 92557 | <1% | 1,880 | $79K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 338 | $78K |
| 87535 | <1% | 2,216 | $76K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 447 | $76K |
| 96900 | <1% | 2,599 | $75K | |
| 74183 | <1% | 201 | $75K | |
| 86706 | <1% | 8,564 | $75K | |
| 83735 | <1% | 20,420 | $73K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 131 | $73K |
| 83540 | <1% | 16,109 | $70K | |
| 81361 | <1% | 583 | $69K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,604 | $68K |
| 87800 | <1% | 2,003 | $68K | |
| 90480 | <1% | 1,868 | $67K | |
| 87340 | <1% | 8,526 | $67K | |
| 73630 | <1% | 2,894 | $67K | |
| 76801 | <1% | 538 | $67K | |
| 72131 | <1% | 590 | $66K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,864 | $66K |
| 83970 | <1% | 1,827 | $65K | |
| 81243 | <1% | 1,392 | $63K | |
| 84702 | <1% | 8,880 | $63K | |
| 91320 | <1% | 975 | $61K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 2,993 | $60K |
| G0378 | Hospital observation service, per hour | <1% | 58 | $60K |
| 83880 | <1% | 3,151 | $60K | |
| D1206 | Topical application of fluoride varnish | <1% | 10,103 | $60K |
| 73110 | <1% | 2,708 | $60K | |
| 72197 | <1% | 142 | $59K | |
| 31575 | <1% | 473 | $59K | |
| 85610 | <1% | 22,298 | $59K | |
| 90837 | Psychotherapy session, about an hour | <1% | 520 | $58K |
| 12002 | <1% | 194 | $57K | |
| D9310 | <1% | 2,054 | $57K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,235 | $57K |
| 92133 | <1% | 1,424 | $56K | |
| 77061 | <1% | 420 | $56K | |
| 73610 | <1% | 2,707 | $55K | |
| 88142 | <1% | 2,351 | $55K | |
| 92567 | <1% | 2,186 | $54K | |
| 82805 | <1% | 6,002 | $53K | |
| 81401 | <1% | 569 | $52K | |
| 90732 | <1% | 568 | $52K | |
| 87653 | <1% | 1,735 | $51K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 6,935 | $50K |
| 99051 | <1% | 4,355 | $49K | |
| 90734 | <1% | 958 | $49K | |
| 87631 | <1% | 1,207 | $49K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 350 | $49K |
| 87517 | <1% | 1,102 | $49K | |
| 84100 | <1% | 14,826 | $48K | |
| 92015 | Determination of refractive state | <1% | 2,018 | $47K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,619 | $47K |
| 73030 | <1% | 2,348 | $47K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,931 | $46K |
| 36000 | <1% | 97 | $46K | |
| 81001 | <1% | 24,545 | $45K | |
| 90670 | <1% | 3,085 | $44K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,557 | $44K |
| 88341 | <1% | 360 | $44K | |
| 92579 | <1% | 772 | $43K | |
| 72128 | <1% | 439 | $43K | |
| 96127 | <1% | 16,663 | $42K | |
| 73562 | <1% | 1,197 | $42K | |
| 74178 | <1% | 117 | $42K | |
| 81257 | <1% | 581 | $40K | |
| 87522 | Neg quan hep c or qual rna | <1% | 905 | $39K |
| 20610 | <1% | 270 | $39K | |
| 93017 | <1% | 585 | $38K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 192 | $37K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 103 | $37K |
| 83001 | <1% | 2,034 | $37K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 28 | $37K |
| 81025 | <1% | 9,612 | $36K | |
| 86762 | <1% | 2,779 | $36K | |
| 92250 | <1% | 865 | $35K | |
| 85730 | <1% | 11,363 | $35K | |
| 92582 | <1% | 371 | $35K | |
| 84146 | <1% | 1,785 | $35K | |
| 99493 | <1% | 805 | $34K | |
| S9485 | Crisis intervention mental health services, per diem | <1% | 31 | $34K |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 373 | $34K |
| 82951 | <1% | 2,843 | $34K | |
| 73502 | <1% | 1,212 | $34K | |
| 86765 | <1% | 2,848 | $33K | |
| 77080 | <1% | 951 | $33K | |
| 84403 | <1% | 1,270 | $32K | |
| 84703 | <1% | 6,069 | $32K | |
| 0072A | <1% | 766 | $31K | |
| 73590 | <1% | 1,957 | $31K | |
| 0071A | <1% | 859 | $31K | |
| 11721 | <1% | 832 | $31K | |
| 84402 | <1% | 1,206 | $30K | |
| 86787 | <1% | 2,881 | $30K | |
| 82948 | <1% | 21,566 | $30K | |
| 92550 | <1% | 903 | $30K | |
| 88313 | <1% | 408 | $30K | |
| 86160 | <1% | 1,688 | $30K | |
| 84153 | <1% | 2,137 | $30K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 792 | $29K |
| 71271 | <1% | 135 | $29K | |
| 85240 | <1% | 1,447 | $29K | |
| 83002 | <1% | 1,610 | $29K | |
| 86704 | <1% | 3,068 | $28K | |
| 82043 | <1% | 6,213 | $28K | |
| 82670 | <1% | 1,029 | $28K | |
| 88312 | <1% | 1,230 | $28K | |
| 88342 | <1% | 571 | $28K | |
| 93247 | <1% | 199 | $27K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 382 | $27K |
| 90648 | <1% | 3,463 | $26K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 12,529 | $26K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 28 | $26K |
| 88304 | <1% | 583 | $26K | |
| 87338 | <1% | 2,476 | $26K | |
| 11900 | <1% | 231 | $26K | |
| 85007 | <1% | 9,400 | $26K | |
| T2022 | Case management, per month | <1% | 544 | $25K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 53 | $25K |
| 81400 | <1% | 566 | $25K | |
| 87486 | <1% | 1,633 | $25K | |
| 29580 | <1% | 254 | $25K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 767 | $25K |
| 94726 | <1% | 445 | $25K | |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 15 | $25K |
| 94729 | <1% | 638 | $24K | |
| 86140 | <1% | 7,665 | $24K | |
| 17110 | <1% | 123 | $24K | |
| D0330 | Panoramic radiographic image | <1% | 1,598 | $24K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 282 | $24K |
| 82274 | <1% | 2,155 | $24K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,313 | $24K |
| 81003 | <1% | 9,299 | $24K | |
| 81255 | <1% | 571 | $24K | |
| 51798 | <1% | 313 | $24K | |
| 76830 | Ultrasound, transvaginal | <1% | 305 | $24K |
| 90723 | <1% | 3,041 | $23K | |
| 96167 | <1% | 532 | $23K | |
| 81200 | <1% | 571 | $22K | |
| 81251 | <1% | 570 | $22K | |
| 83516 | <1% | 1,804 | $22K | |
| 99201 | <1% | 339 | $21K | |
| 90716 | <1% | 1,274 | $20K | |
| 92002 | <1% | 422 | $20K | |
| 73090 | <1% | 1,344 | $20K | |
| 86235 | <1% | 418 | $20K | |
| 58300 | <1% | 144 | $20K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 116 | $20K |
| 87581 | <1% | 1,632 | $20K | |
| 93320 | <1% | 381 | $19K | |
| 82627 | <1% | 884 | $19K | |
| 96161 | <1% | 3,520 | $19K | |
| 93325 | <1% | 590 | $19K | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,857 | $19K |
| 31231 | <1% | 104 | $19K | |
| 90707 | <1% | 1,328 | $19K | |
| 85307 | <1% | 1,425 | $19K | |
| 81260 | <1% | 571 | $18K | |
| 85306 | <1% | 1,385 | $18K | |
| 93971 | <1% | 247 | $18K | |
| 97167 | <1% | 139 | $18K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 99 | $17K |
| 85303 | <1% | 1,391 | $17K | |
| 73080 | <1% | 925 | $17K | |
| 97010 | <1% | 2,404 | $16K | |
| 85300 | <1% | 1,755 | $16K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 3,972 | $16K |
| 93798 | <1% | 751 | $16K | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,544 | $16K |
| 86003 | <1% | 580 | $16K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 12 | $16K |
| 97760 | <1% | 166 | $16K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,894 | $16K |
| 80320 | <1% | 5,247 | $15K | |
| 73140 | <1% | 767 | $15K | |
| 0081A | <1% | 335 | $15K | |
| 82570 | <1% | 3,596 | $15K | |
| 83020 | <1% | 1,029 | $15K | |
| 85305 | <1% | 1,353 | $15K | |
| 90681 | <1% | 2,030 | $15K | |
| 96040 | <1% | 163 | $15K | |
| 76870 | <1% | 158 | $15K | |
| 86225 | <1% | 1,421 | $14K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 2,276 | $14K |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 15 | $14K |
| 82784 | <1% | 1,116 | $14K | |
| 72100 | <1% | 486 | $14K | |
| 84484 | <1% | 11,052 | $14K | |
| D1110 | Prophylaxis - adult | <1% | 1,753 | $14K |
| 93226 | <1% | 192 | $13K | |
| 72070 | <1% | 420 | $13K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 4,235 | $13K |
| 86038 | <1% | 1,422 | $12K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 514 | $12K |
| 90662 | <1% | 691 | $12K | |
| 87186 | <1% | 2,562 | $12K | |
| 70496 | <1% | 79 | $12K | |
| 82746 | <1% | 1,052 | $12K | |
| 84156 | <1% | 3,627 | $11K | |
| 85651 | <1% | 4,616 | $11K | |
| 82248 | <1% | 2,571 | $11K | |
| 83883 | <1% | 567 | $11K | |
| 86334 | <1% | 669 | $11K | |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 80 | $11K |
| 93246 | <1% | 239 | $10K | |
| 70498 | <1% | 40 | $10K | |
| 82247 | <1% | 2,230 | $10K | |
| 90656 | <1% | 851 | $10K | |
| 0082A | <1% | 228 | $10K | |
| D9995 | <1% | 627 | $10K | |
| 90633 | <1% | 1,454 | $10K | |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 48 | $10K |
| 86708 | <1% | 1,012 | $10K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 940 | $10K |
| D0272 | Bitewings - two radiographic images | <1% | 3,085 | $10K |
| 86255 | <1% | 922 | $10K | |
| 73070 | <1% | 564 | $10K | |
| 0154A | <1% | 237 | $9K | |
| 86376 | <1% | 705 | $9K | |
| 83690 | <1% | 9,436 | $9K | |
| 83615 | <1% | 2,324 | $9K | |
| 73700 | <1% | 40 | $9K | |
| 80348 | <1% | 712 | $9K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 581 | $9K |
| D9223 | Deep sedation/general anesthesia - each subsequent 15 minute increment | <1% | 25 | $9K |
| 73552 | <1% | 573 | $9K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 887 | $9K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,800 | $9K |
| 59200 | <1% | 20 | $9K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 12,208 | $9K |
| 70491 | <1% | 40 | $9K | |
| 86592 | <1% | 2,081 | $8K | |
| 92650 | <1% | 275 | $8K | |
| 59841 | <1% | 13 | $8K | |
| 81002 | <1% | 2,448 | $8K | |
| 84305 | <1% | 391 | $8K | |
| 87521 | Neg quan hep c or qual rna | <1% | 216 | $8K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 541 | $8K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 84 | $8K |
| 73060 | <1% | 554 | $8K | |
| 52000 | <1% | 17 | $8K | |
| D9990 | <1% | 1,830 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,953 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,362 | $7K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 174 | $7K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 869 | $7K |
| 92504 | <1% | 172 | $7K | |
| 83498 | <1% | 249 | $7K | |
| 86735 | <1% | 694 | $7K | |
| 82550 | <1% | 3,151 | $7K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 845 | $6K |
| 90661 | <1% | 320 | $6K | |
| 95886 | <1% | 59 | $6K | |
| 82977 | <1% | 1,080 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,036 | $6K |
| 59425 | <1% | 100 | $6K | |
| 99188 | <1% | 639 | $6K | |
| 97810 | <1% | 316 | $6K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $6K |
| 92555 | <1% | 176 | $6K | |
| 72141 | <1% | 13 | $6K | |
| 82533 | <1% | 375 | $6K | |
| 99384 | <1% | 84 | $6K | |
| 84550 | <1% | 1,714 | $6K | |
| 90678 | <1% | 134 | $6K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 551 | $6K |
| 99383 | <1% | 86 | $5K | |
| 25605 | <1% | 15 | $5K | |
| 92587 | <1% | 225 | $5K | |
| 88141 | <1% | 304 | $5K | |
| 84481 | <1% | 394 | $5K | |
| 84165 | <1% | 707 | $5K | |
| 43235 | <1% | 12 | $5K | |
| 96523 | <1% | 86 | $5K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 63 | $5K |
| 88173 | <1% | 57 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,832 | $5K |
| 0031A | <1% | 124 | $5K | |
| 85045 | <1% | 1,513 | $5K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,331 | $5K |
| 82105 | <1% | 343 | $4K | |
| 72170 | <1% | 287 | $4K | |
| 97811 | <1% | 327 | $4K | |
| 97166 | <1% | 40 | $4K | |
| 86593 | <1% | 1,225 | $4K | |
| 87507 | <1% | 37 | $4K | |
| J1230 | Injection, methadone hcl, up to 10 mg | <1% | 1,307 | $4K |
| 96380 | <1% | 289 | $4K | |
| 76775 | <1% | 108 | $4K | |
| 82652 | <1% | 119 | $4K | |
| 95816 | <1% | 13 | $4K | |
| 92588 | <1% | 132 | $4K | |
| 87070 | <1% | 831 | $4K | |
| 82785 | <1% | 291 | $4K | |
| 80165 | <1% | 485 | $4K | |
| 85379 | <1% | 1,886 | $4K | |
| 99494 | <1% | 93 | $4K | |
| 92201 | <1% | 157 | $4K | |
| 73521 | <1% | 129 | $4K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 92 | $4K |
| 10060 | <1% | 25 | $4K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 24 | $4K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 133 | $4K |
| D9222 | <1% | 25 | $4K | |
| 0003A | <1% | 84 | $4K | |
| 90694 | <1% | 181 | $4K | |
| 69210 | <1% | 91 | $4K | |
| 88108 | <1% | 122 | $4K | |
| 82378 | <1% | 187 | $3K | |
| 74174 | <1% | 12 | $3K | |
| 72190 | <1% | 176 | $3K | |
| 74018 | <1% | 141 | $3K | |
| 84445 | <1% | 67 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,831 | $3K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 544 | $3K |
| 86800 | <1% | 219 | $3K | |
| 87205 | <1% | 1,298 | $3K | |
| 11981 | <1% | 17 | $3K | |
| 92586 | <1% | 25 | $3K | |
| D0274 | Bitewings - four radiographic images | <1% | 820 | $3K |
| 73120 | <1% | 107 | $3K | |
| 90653 | <1% | 221 | $3K | |
| 97602 | <1% | 17 | $3K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,321 | $3K |
| 86320 | <1% | 95 | $3K | |
| 82803 | <1% | 1,350 | $3K | |
| 90700 | <1% | 406 | $2K | |
| 83525 | <1% | 184 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 17 | $2K |
| 85018 | <1% | 997 | $2K | |
| 88112 | <1% | 32 | $2K | |
| 83519 | <1% | 131 | $2K | |
| 96402 | <1% | 54 | $2K | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 557 | $2K |
| 0074A | <1% | 53 | $2K | |
| 94770 | <1% | 48 | $2K | |
| 99243 | <1% | 15 | $2K | |
| 96411 | <1% | 39 | $2K | |
| 86430 | <1% | 431 | $2K | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 2,129 | $2K |
| 99241 | <1% | 15 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,179 | $2K |
| 83521 | <1% | 110 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 917 | $2K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 955 | $2K |
| 91318 | <1% | 410 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,153 | $2K |
| D2330 | <1% | 24 | $2K | |
| 17250 | <1% | 12 | $2K | |
| D1310 | <1% | 255 | $2K | |
| 86709 | <1% | 173 | $2K | |
| 93923 | <1% | 15 | $2K | |
| 88184 | <1% | 27 | $2K | |
| 0083A | <1% | 34 | $2K | |
| 92020 | <1% | 61 | $2K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 169 | $2K |
| H0049 | Alcohol and/or drug screening | <1% | 26 | $1K |
| 85014 | <1% | 618 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 283 | $1K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 35 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 745 | $1K |
| 86008 | <1% | 17 | $1K | |
| 0012A | <1% | 63 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,042 | $1K |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 27 | $1K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 62 | $1K |
| 86146 | <1% | 52 | $1K | |
| 58301 | <1% | 13 | $1K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 380 | $1K |
| 86147 | <1% | 58 | $1K | |
| 83605 | <1% | 1,334 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,635 | $1K |
| OP250 | <1% | 856 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,990 | $1K |
| 86258 | <1% | 61 | $1K | |
| 90474 | <1% | 257 | $1K | |
| 82157 | <1% | 42 | $1K | |
| 92202 | <1% | 99 | $1K | |
| C1769 | Guide wire | <1% | 73 | $1K |
| 86304 | <1% | 60 | $1K | |
| G0271 | Medical nutrition therapy, reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition, or treatment regimen (including additional hours needed for renal disease), group (2 or more individuals), each 30 minutes | <1% | 89 | $1K |
| 87593 | <1% | 22 | $1K | |
| 84478 | <1% | 281 | $1K | |
| 82330 | <1% | 1,308 | $1K | |
| 94760 | <1% | 1,752 | $1K | |
| 93308 | <1% | 12 | $998.84 | |
| 96376 | <1% | 994 | $987.20 | |
| 90647 | <1% | 193 | $977.82 | |
| 81005 | <1% | 745 | $957.47 | |
| 90739 | <1% | 12 | $944.15 | |
| 83695 | <1% | 80 | $938.73 | |
| 99429 | <1% | 256 | $907.50 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 604 | $890.66 |
| 0011A | <1% | 69 | $885.74 | |
| 85384 | <1% | 411 | $866.10 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 4,784 | $837.77 |
| 73100 | <1% | 26 | $814.42 | |
| 0173A | <1% | 42 | $779.70 | |
| 84480 | <1% | 80 | $779.20 | |
| 73560 | <1% | 29 | $767.65 | |
| 91319 | <1% | 198 | $740.15 | |
| 92285 | <1% | 27 | $733.67 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 849 | $716.21 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 21 | $686.80 |
| 97022 | <1% | 43 | $671.56 | |
| 90672 | <1% | 186 | $646.72 | |
| 92570 | <1% | 16 | $621.67 | |
| 99421 | <1% | 13 | $617.36 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,912 | $615.93 |
| 84432 | <1% | 42 | $602.01 | |
| V2632 | Posterior chamber intraocular lens | <1% | 19 | $580.18 |
| 88104 | <1% | 14 | $562.12 | |
| 84630 | <1% | 64 | $556.23 | |
| 82465 | <1% | 203 | $550.66 | |
| 86231 | <1% | 58 | $550.07 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 592 | $543.72 |
| 90696 | <1% | 72 | $527.14 | |
| 92227 | <1% | 35 | $524.82 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 17 | $508.67 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,581 | $477.76 |
| 82024 | <1% | 12 | $468.45 | |
| 83718 | <1% | 125 | $467.45 | |
| 82150 | <1% | 380 | $463.00 | |
| 76604 | <1% | 12 | $461.55 | |
| 73000 | <1% | 17 | $455.39 | |
| 85613 | <1% | 61 | $443.10 | |
| 92552 | <1% | 12 | $431.31 | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 52 | $417.72 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,616 | $414.28 |
| 92025 | <1% | 13 | $410.48 | |
| 82525 | <1% | 39 | $407.04 | |
| 92551 | <1% | 2,939 | $397.25 | |
| 83010 | <1% | 37 | $389.14 | |
| J1815 | Injection, insulin, per 5 units | <1% | 245 | $374.87 |
| 85732 | <1% | 68 | $374.15 | |
| 90381 | <1% | 43 | $353.18 | |
| 87040 | <1% | 191 | $322.94 | |
| 87081 | <1% | 114 | $310.10 | |
| 82172 | <1% | 18 | $296.80 | |
| 82952 | <1% | 59 | $295.89 | |
| 0073A | <1% | 15 | $281.33 | |
| 82947 | <1% | 224 | $278.33 | |
| 84270 | <1% | 12 | $275.77 | |
| 84681 | <1% | 15 | $270.52 | |
| 99406 | <1% | 293 | $261.04 | |
| D0191 | <1% | 1,043 | $260.39 | |
| 83520 | <1% | 14 | $258.22 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 159 | $257.24 |
| 88280 | <1% | 15 | $255.32 | |
| 85301 | <1% | 28 | $249.87 | |
| D0171 | <1% | 77 | $245.55 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,455 | $240.08 |
| 83921 | <1% | 13 | $218.48 | |
| 90473 | <1% | 96 | $213.93 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 223 | $211.72 |
| 90620 | <1% | 12 | $195.15 | |
| 83993 | <1% | 12 | $185.46 | |
| 82103 | <1% | 13 | $184.10 | |
| 80178 | <1% | 29 | $180.47 | |
| 0502F | <1% | 16 | $179.48 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 1,945 | $178.03 |
| 1159F | <1% | 7,526 | $176.15 | |
| D0603 | <1% | 1,906 | $160.88 | |
| 99173 | <1% | 3,308 | $159.43 | |
| 99152 | <1% | 28 | $148.47 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 113 | $145.90 |
| 84460 | <1% | 30 | $143.63 | |
| 86707 | <1% | 12 | $134.70 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 25 | $129.71 |
| 80069 | <1% | 14 | $127.26 | |
| 96368 | <1% | 27 | $126.21 | |
| 90380 | <1% | 22 | $125.58 | |
| 3075F | <1% | 13,208 | $117.71 | |
| 94727 | <1% | 12 | $115.83 | |
| 86705 | <1% | 13 | $114.07 | |
| 98968 | <1% | 30 | $101.47 | |
| 82085 | <1% | 18 | $101.46 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 385 | $97.08 |
| J1071 | Injection, testosterone cypionate, 1 mg | <1% | 40 | $97.05 |
| 82010 | <1% | 89 | $93.25 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 28 | $90.53 |
| 82310 | <1% | 28 | $88.73 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 12 | $81.70 |
| D0602 | <1% | 546 | $77.43 | |
| 80051 | <1% | 12 | $72.29 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 12 | $69.36 |
| 82397 | <1% | 17 | $60.71 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 71 | $52.98 |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 1,061 | $38.23 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 26 | $33.77 |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | <1% | 63 | $30.87 |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | <1% | 30 | $26.46 |
| 82962 | <1% | 256 | $22.98 | |
| 86141 | <1% | 53 | $22.61 | |
| 86701 | <1% | 63 | $20.00 | |
| 90685 | <1% | 22 | $17.85 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 205 | $14.23 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 57 | $10.45 |
| G0008 | Administration of influenza virus vaccine | <1% | 155 | $8.70 |
| 80354 | <1% | 49 | $5.05 | |
| 3078F | <1% | 52,457 | $2.85 | |
| 99024 | <1% | 58 | $0.12 | |
| 1160F | <1% | 5,672 | $0.01 | |
| 3079F | 0% | 11,785 | $0.00 | |
| 3080F | 0% | 3,282 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 232 | $0.00 |
| 3074F | 0% | 46,191 | $0.00 | |
| 88720 | 0% | 116 | $0.00 | |
| D1330 | 0% | 771 | $0.00 | |
| D0601 | 0% | 644 | $0.00 | |
| 82270 | 0% | 53 | $0.00 | |
| 1220F | 0% | 510 | $0.00 | |
| 3072F | 0% | 33 | $0.00 | |
| 3044F | 0% | 65 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 40 | $0.00 |
| 71020 | 0% | 12 | $0.00 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 17 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 7,293 | $0.00 |
| 99499 | 0% | 4,942 | $0.00 | |
| 99080 | 0% | 3,818 | $0.00 | |
| 2022F | 0% | 106 | $0.00 | |
| 3077F | 0% | 9,428 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 86 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 66 | $0.00 |
| 48510 | 0% | 25 | $0.00 | |
| G0445 | High intensity behavioral counseling to prevent sexually transmitted infection; face-to-face, individual, includes: education, skills training and guidance on how to change sexual behavior; performed semi-annually, 30 minutes | 0% | 27 | $0.00 |
| 99242 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.